Cytochrome p-450 polymorphisms and response to clopidogrel.
By J. Mega, S. Close, S. Wiviott, Lei-Bin Shen, R. Hockett, J. Brandt, J. Walker, E. Antman, W. Macias, E. Braunwald and 1 more. New England Journal of Medicine, 2009
2,536 citations recorded by the source corpus.
Subfields: Biochemistry, Cardiology and Cardiovascular Medicine, Pharmacology
View Paper: https://www.semanticscholar.org/paper/cafc03db7800e6af139b8af5a2ab0268166b2ff1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biochemistry
In Cardiology and Cardiovascular Medicine
- Peter C. Austin
- G. Fonarow
- J. Halperin
- Judith Hochman
- M. Creager
- C. Yancy
- Roger Mundry
- M. Gheorghiade
In Pharmacology
Citations in the corpus
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite (2010, background): “…on the pharmacodynamic response of clopidogrel, and studies on the effect of genetic polymorphism of CYP2C19 on the clinical outcomes in patients treated with clopidogrel (Hulot et al., 2006; Suh et al., 2006; Brandt et al., 2007; Farid et al., 2007, 2008; Mega et al., 2009; Simon et al., 2009).”
- Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “Numerous clinical studies have confirmed that CYP2C19 PMs have significantly lower anticoagulation effect of clopidogrel,which is associatedwith an increased risk of major adverse cardiovascular events (Collet et al., 2009; Mega et al., 2009; Simon et al., 2009; Sofi et al., 2011).”
- Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. (2009, background): “ite primary efficacy outcome of the risk of cardiovascular events and death.(18) In”
- 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “In TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel—Thrombolysis In Myocardial Infarction)(285) and 3 cohort studies, patients who were carriers of the reduced-function CYP2C19*2 allele had significantly lower levels of the active m”